10x Genomics (10x Genomics) Change In Receivables : $-13.4 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is 10x Genomics Change In Receivables?

10x Genomics's change in receivables for the quarter that ended in Mar. 2024 was $23.5 Mil. It means 10x Genomics's Accounts Receivable declined by $23.5 Mil from Dec. 2023 to Mar. 2024 .

10x Genomics's change in receivables for the fiscal year that ended in Dec. 2023 was $-10.6 Mil. It means 10x Genomics's Accounts Receivable increased by $10.6 Mil from Dec. 2022 to Dec. 2023 .

10x Genomics's Accounts Receivable for the quarter that ended in Mar. 2024 was $91.3 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. 10x Genomics's Days Sales Outstanding for the three months ended in Mar. 2024 was 59.09.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. 10x Genomics's liquidation value for the three months ended in Mar. 2024 was $277.8 Mil.

10x Genomics Change In Receivables Historical Data

The historical data trend for 10x Genomics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Change In Receivables Chart

10x Genomics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-5.28

-17.85

-34.04

-18.95

-10.61

10x Genomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															26.28	-9.75	-16.17	-10.97	23.52

10x Genomics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.4 Mil.

10x Genomics (NAS:TXG) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

10x Genomics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	91.305	/	141.006	*	91
=	59.09

2. In Ben Graham's calculation of liquidation value, 10x Genomics's accounts receivable are only considered to be worth 75% of book value:

10x Genomics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	371.814	-	204.079	+	0.75 * 91.305	+	0.5 * 83.189
=	277.8

10x Genomics Change In Receivables Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

10x Genomics (10x Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

1KJ:Germany

Address

6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588

Website

https://www.10xgenomics.com

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Executives

Serge Saxonov	director, 10 percent owner, officer: Chief Executive Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur	officer: Chief Commercial Officer	C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson	director, officer: See Remarks	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear	officer: Chief Financial Officer	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel	director	10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen	director	THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield	officer: Chief Commercial Officer	6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts	director	C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc	10 percent owner	2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006